BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery (NCT06998732) | Clinical Trial Compass
Not Yet RecruitingPhase 4
BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery
40 participantsStarted 2025-06-01
Plain-language summary
This study intends to measure the ED95 of remimazolam-assisted sedation in arteriovenous fistula creation by BCD.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18-65 years old (including borderline values).
* Elective surgical patients under local anaesthesia for operation of AVF
* Voluntary participation in this study and signing of informed consent.
* American Society of Anesthesiologists (ASA) classification \< Grade IV.
* BMI range: 18-28kg/m2 (including borderline values).
Exclusion Criteria:
* hypersensitivity to remimazolam or benzodiazepines.
* patients with severe cardiac, pulmonary, neurological diseases or liver failure. -- Preoperative use of sedative drugs, anticonvulsants, etc.
* patients who cannot cooperate with postoperative recovery or follow-up.
* vulnerable groups, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, illiterates, etc.